Market News & Trends
Cytokinetics Announces Start of Phase II Clinical Trial
Cytokinetics, Inc. recently announced that its first Phase II clinical trial of CK-2127107, a novel fast skeletal muscle troponin activator, in patients with spinal muscular…
Abbott & UCSF Discover New Virus is Linked to Hepatitis C
Abbott and University of California San Francisco (UCSF) published research identifying a newly discovered human virus, known as human pegivirus 2 (HPgV-2), and proving it…
Neon Therapeutics & BMS Enter Clinical Trial Collaboration
Neon Therapeutics recently announced a clinical trial collaboration with Bristol-Myers Squibb. The collaboration will evaluate the combination of Neon Therapeutics’ proprietary personalized neoantigen vaccine, NEO-PV-01,…
Neovacs SA Signs Strategic Partnering Agreement With CKD Pharmaceutical
Neovacs recently announced the signature of an exclusive licensing agreement with Chong Kun Dang (CKD) Pharmaceutical Corp. (Seoul, South Korea) to market the IFNa-Kinoïd for…
Lightlake Therapeutics Receives Milestone Payment for Nasal Spray
Lightlake Therapeutics Inc. recently announced it has received a $2-million milestone payment from Adapt Pharma Limited. This milestone payment was triggered by the US FDA…
KemPharm Submits NDA for KP201/APAP & Requests Priority Review
KemPharm, Inc. recently announced it has submitted an NDA under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for KP201/APAP to the US…
Egalet Submits NDA for Morphine Sulfate ER Tablets
Egalet Corporation recently announced the company has submitted an NDA for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to…
MedPharm Announces Formation of US Subsidiary & First Appointment
MedPharm recently announced the formation of its new US-based laboratories, MP Pharma Services Inc. With a targeted operational date in Q1 2016, the services offered…
MGB Biopharma Successfully Completes Phase I Clinical Trial
MGB Biopharma recently announced it has successfully completed a Phase I clinical trial of an oral formulation of its lead product, MGB-BP-3, which is being…
Protea Announces Biopharm Industry Collaboration With Agilent
Protea Biosciences Group, Inc. recently announced it is collaborating with Agilent Technologies, Inc. to address customer challenges within existing Biopharma bioanalytical workflows in order to…